New Managing Director at BIOMEX!
Dr. Klaus Esperschidt is the new Chief Operating Officer and Managing Director at BIOMEX and is supporting the company in its growth into new markets.
BIOMEX supports Goethe-Corona Fund
BIOMEX supports the Goethe Corona Fund, a joint project of the University of Frankfurt and the University Hospital Frankfurt for Corona emergency aid in India.
COVID-19: Layman study for rapid antigen self-tests in just one week!
In just one week, BIOMEX planned, organized and conducted a COVID-19 layman study for rapid antigen self-testing.
BIOMEX develops unique SARS-CoV-2 immunity seroconversion panels
To support the IvD and life sciences industries in their efforts against the COVID-19 pandemic, BIOMEX is developing new and unique SARS-CoV-2 immunity seroconversion panels.
Anti-SARS-CoV-2 Tests: Manufacturer independent IgG and IgM controls available
DiaMex GmbH, a sister company of BIOMEX, has developed anti-SARS-CoV-2 IgG and IgM controls that enable quality control of numerous SARS-CoV-2 antibody assays worldwide.
The new L2 lab facility can process up to 3.000 PCR tests per day
The new L2 laboratory facility of BIOMEX, which was set up within two weeks, can process up to 3000 PCR tests per day.
SARS-CoV-2 samples available
In recent weeks, BIOMEX has collected more than 900 sequential bleeds from over 150 recovered COVID-19 patients to enable the progress of clinical validation of the test systems.
SARS-CoV-2 antibody tests development: BIOMEX started to collect serum
To support research in developing SARS-CoV-2 antibody tests and establishing a cut-off value, BIOMEX collects serum from COVID-19 positive patients after quarantine.
New validation panels for various HCV assays
BIOMEX offers new validation and seroconversion panels for HCV to advance IVD product development and ensure compliance with quality standards.
